TNXP ..Phase 3 interim results of the posttraumatic stress disorder (PTSD) trial expected during this Quarter .Extremely low valuation of only $13 million this could run towards $10 and higher especially on positive phase 3 outcome .
from Zacks article :
We are looking forward to the results of the interim analysis for the RECOVERY trial in the first quarter of 2020, and pending the outcome of that analysis, topline results in the second quarter of 2020. Based on the results of 2.8 mg TNX-102 SL in the AFFIRM trial, we believe there is a high likelihood of success for 5.6 mg TNX-102 SL in the RELIEF trial, and we anticipate updates regarding an interim analysis for that trial in 2020.
News 
Market Data 
Discover 
